Abstract
Background
Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a rare, Non-Hodgkin
lymphoma arising in the capsule of breast implants. BIA-ALCL presents as a recurrent
effusion and/or mass. Tumours exhibit CD30 expression and are negative for Anaplastic
Lymphoma Kinase (ALK). We report the multi-disciplinary management of the UK series
and how the stage of disease may be used to stratify treatment.
Methods
Between 2012 and 2016, 23 cases of BIA-ALCL were diagnosed in 15 regional centres
throughout the UK. Data on breast implant surgeries, clinical features, treatment
and follow-up were available for 18 patients.
Results
The mean lead-time from initial implant insertion to diagnosis was 10 years (range:
3–16). All cases were observed in patients with textured breast implants or expanders.
Fifteen patients with breast implants presented with stage I disease (capsule confined),
and were treated with implant removal and capsulectomy. One patient received adjuvant
chest-wall radiotherapy. Three patients presented with extra-capsular masses (stage
IIA). In addition to explantation, capsulectomy and excision of the mass, all patients
received neo-/adjuvant chemotherapy with CHOP as first line. One patient progressed
on CHOP but achieved pathological complete response (pCR) with Brentuximab Vedotin.
After a mean follow-up of 23 months (range: 1–56) all patients reported here remain
disease-free.
Discussion
BIA-ALCL is a rare neoplasm with a good prognosis. Our data support the recommendation
that stage I disease be managed with surgery alone. Adjuvant chemotherapy may be required
for more invasive disease and our experience has shown the efficacy of Brentuximab
as a second line treatment.
Keywords
To read this article in full you will need to make a payment
Subscribe to European Journal of Surgical Oncology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
U.S. Food and Drug Administration. Available from: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm239996.htm.
MHRA. Breast implants – report cases of anaplastic large cell lymphoma (ALCL) Available from: https://www.gov.uk/drug-device-alerts/medical-device-alert-breast-implants-report-cases-of-anaplastic-large-cell-lymphoma-alcl.
- Anaplastic T-cell lymphoma in proximity to a saline-filled breast implant.Plast Reconstr Surg. 1997; 100: 554-555
- Lymphomas associated with breast implants: a review of the literature.Aesthet Surg J. 2015; 35: 533-544
- Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases.Plast Reconstr Surg. 2015; 136: 553e-554e
- Anaplastic large-cell lymphoma in women with breast implants.JAMA. 2008; 300: 2030-2035
- Department of health. Therapeutic goods administration.2016 (Available from:)
- Discussion: breast implant informed consent should include the risk of anaplastic large cell lymphoma.Plast Reconstr Surg. 2016; 137: 1123
- Anaplastic large cell lymphoma (ALCL) and breast implants: breaking down the evidence.Mutat Res Rev Mutat Res. 2014; 762: 123-132
- T regulatory cells and TH17 cells in peri-silicone implant capsular fibrosis.Plast Reconstr Surg. 2012; 129: 327e-337e
- Helicobacter pylori infection and gastric lymphoma.N Engl J Med. 1994; 330: 1267-1271
- Gastric MALT lymphoma: a model of chronic inflammation-induced tumor development.Nat Rev Gastroenterol Hepatol. 2010; 7: 336-346
- Anaplastic large cell lymphoma arising in a saline breast implant capsule after tissue expander breast reconstruction.Ann Plast Surg. 2007; 59: 56-57
- Managing late periprosthetic fluid collections (seroma) in patients with breast implants: a consensus panel recommendation and review of the literature.Plast Reconstr Surg. 2011; 128: 1-7
- Anaplastic large cell lymphoma and breast implants: results from a structured expert consultation process.Plast Reconstr Surg. 2011; 128: 629-639
- Anaplastic large cell lymphoma occurring in association with breast implants: review of pathologic and immunohistochemical features in 103 cases.Appl Immunohistochem Mol Morphol. 2013; 21: 13-20
- Breast implant-associated anaplastic large cell lymphoma: a systematic review of the literature and mini-meta analysis.Curr Hematol Malig Rep. 2013; 8: 196-210
- Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma.J Clin Oncol. 2016; 34: 160-168
- The biology and management of systemic anaplastic large cell lymphoma.Blood. 2015; 126: 17-25
- Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.J Clin Oncol. 2012; 30: 2190-2196
- Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.N Engl J Med. 2010; 363: 1812-1821
- Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma.Onco Targets Ther. 2016; 9: 2027-2034
Breast implant associated ALCL: PROFILE project. Available from: www.thepsf.org/research/clinical-impact/profile-investigating-breast-implant-associated-alcl.htm.
- Anaplastic large cell lymphoma in a reconstructed breast using a silicone implant: a UK case report.J Plast Reconstr Aesthet Surg. 2014; 67: 561-563
Johnson L, O'Donoghue J, Stark H, et al. Breast implant associated analplastic large cell lymphoma (BIA-ALCL) – the UK experience and first reported case of neoadjuvant Brentuximab. 39th annual San Antonio breast cancer symposium; 6–10 December 2016; San Antonio, Texas, USA2016.
Breast cancer care – breast reconstruction. Available from: www.breastcancercare.org.uk/breast-reconstruction-potential-problems.
- BIA-ALCL.2016 (Available from)
- Reconstructive and Aesthetic Surgeons: ALCL risk from breast implants.2016 (Available from:)
- Breast implant informed consent should include the risk of anaplastic large cell lymphoma.Plast Reconstr Surg. 2016; 137: 1117-1122
- Breast implant-associated anaplastic large cell lymphoma: updated results from a structured expert consultation process.Plast Reconstr Surg Glob Open. 2015; 3: e296
Breast and cosmetic implant registry Available from: http://content.digital.nhs.uk/bcir.
- Montgomery (Appellant) v Lanarkshire Health Board (Respondent) (Scotland). 11 March 2015
- The national comprehensive cancer network consensus guidelines for the diagnosis and management of breast implant-associated anaplastic large cell lymphoma. 2017
Article Info
Publication History
Published online: May 18, 2017
Accepted:
May 8,
2017
Identification
Copyright
© 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
